Skip to content Skip to footer
Subscribe Now
Top 20 Vaccines of 2025
TOP 20

Top 20 Vaccines of 2025 

Shots:  Vaccines play a critical role in combating infectious diseases by stimulating antibody production and establishing immune memory. Biopharma companies around the globe continue to drive innovation in vaccine development, targeting both infectious and preventable diseases  The global vaccine market was valued at $87.75B in 2024 and is projected to reach $151.96B by 2033, reflecting…
July 17, 2025

Read more

INSIGHTS+

Know Your Investor: Invus (July’25 Edition)

Shots:      Welcome to the 2025 edition of Know Your Investor, highlighting leading venture capital firms shaping the future of healthcare innovation  This edition highlights Invus, an investment firm focused on supporting life sciences companies committed to advancing breakthroughs that enhance public health  In 2024, Invus invested around $4.15B across six funding rounds, expanding its portfolio…
July 16, 2025

Read more

VIEWPOINTS

Retrieving Olfactory Prowess: Rick Geoffrion from Cyrano Therapeutics in Conversation with PharmaShots 

Shots:  Recently, Cyrano Therapeutics signed a licensing agreement with Resyca, integrating its novel therapy for post-viral smell loss, CYR-064, with Resyca’s Soft Mist Nasal Spray Technology  PharmaShots welcomes Rick Geoffrion, President & CEO of Cyrano Therapeutics, in an illuminating dialogue exchange centered around CYR-064 and its role in treating post-viral hyposmia (smell loss)  Rick highlights…
July 14, 2025

Read more

VIEWPOINTS

Unlocking Approval: Sofie Berg from AbbVie in a Riveting Conversation with PharmaShots 

Shots:  AbbVie adds an eighth indication to Rinvoq’s label with the European Commission’s approval for treating adult patients with giant cell arteritis (GCA)  Sofie Berg, Therapeutic Area Head of International Immunology at AbbVie, in a conversation with PharmaShots, shares insights from the SELECT-GCA trial evaluating Rinvoq in GCA, highlighting both primary and secondary endpoints  Rinvoq…
July 9, 2025

Read more

INSIGHTS+

Key Biosimilars Events of June 2025  

Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         Alvotech & Advanz Pharma Secure the CHMP’s Positive Opinion for AVT06. Our…
July 8, 2025

Read more

VIEWPOINTS

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 

Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 2025

Read more

THOUGHTSPOT

Choose the Right Microplate Reader: Strategic Guide for Advanced Biologics Development

In the competitive and ever-evolving world of biologics and protein therapy, each decision can significantly influence the trajectory of your research outcomes. Among these critical choices, selecting the optimal microplate reader stands out. Far from being just another lab instrument, your choice here can dramatically shape the accuracy, efficiency, and scalability of your scientific discoveries.…
July 7, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)    

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, and Biosimilar. Check out our full report below:  Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD)  Read More: Neurocrine  UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients  Read More: UCB  …
July 4, 2025

Read more

THOUGHTSPOT

Is Addiction Hereditary?

When you think about addiction, you likely wonder if your family history puts you at risk. The answer isn't straightforward, genetics account for 40-60% of addiction vulnerability, while your environment shapes the rest. Your DNA influences how your brain responds to substances, but it doesn't seal your fate. Understanding this genetic component reveals why addiction…
July 4, 2025

Read more

Load more